Response to Bistrian BR. Parenteral Fish-Oil Emulsions in Critically Ill COVID-19 Emulsions.

Autor: Torrinhas RS; Laboratory of Nutrition and Metabolic Surgery (LIM-35), Department of Gastroenterology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil., Calder PC; Human Development & Health, Faculty of Medicine, University of Southampton, Southampton, UK.; NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, UK., Waitzberg DL; Laboratory of Nutrition and Metabolic Surgery (LIM-35), Department of Gastroenterology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
Jazyk: angličtina
Zdroj: JPEN. Journal of parenteral and enteral nutrition [JPEN J Parenter Enteral Nutr] 2020 Sep; Vol. 44 (7), pp. 1169-1170. Date of Electronic Publication: 2020 Jun 24.
DOI: 10.1002/jpen.1933
Abstrakt: In this letter we discuss the proposition of Bristian BR (2020) to use the intravenous administration of fish-oil emulsions in critically ill patients with Coronavirus Disease 2019 (COVID-19). We consider that immune-modulatory properties of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids, rapidly provided in high amounts by fish-oil emulsions, may be important to change the course of COVID-19's death pathway. Prescriptions should be based on body weight (eg, 0.2-g pure fish-oil lipid emulsion/kg body weight/d) and also should consider combining the parenteral administration of fish-oil emulsions with low oral aspirin intake to trigger resolvin synthesis from EPA and DHA.
(© 2020 American Society for Parenteral and Enteral Nutrition.)
Databáze: MEDLINE
Externí odkaz: